BITRC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Biotron Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
3
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Biotron Limited - Rights - Applications Close 18-Nov-2022
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π° Price*
$0.00
*Price may be up to 24 hours old
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in BITRC
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in BITRC
N/A
BITRC investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in BITRC also invest in...
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyβs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.
π Performance (5Yr p.a)
-18.68%
π Share price
$0.01 AUD
𧬠BIOTECHNOLOGY
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
π Performance (5Yr p.a)
10.00%
π Share price
$16.14 AUD
πΈ FINANCIALS
π GLOBAL
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
TECH.AX was created on 2017-04-06 by Global X. The fund's investment portfolio concentrates primarily on information technology equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Morningstar Developed Markets Technology Moat Focus IndexSM (the Index).
π Performance (5Yr p.a)
6.85%
π Share price
$118.39 AUD
π€ TECHNOLOGY
π¦πΊ EX AUSTRALIA
π INDUSTRIALS
π° HIGH DIVIDEND
CNEW.AX was created on 2018-11-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. CNEW.AX gives investors a portfolio of the most fundamentally sound companies in China having the best growth prospects in sectors making up the New Economy, namely technology, health care, consumer staples and consumer discretionary. CNEW.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.
π Performance (5Yr p.a)
-2.29%
π Share price
$7.11 AUD
VESG.AX was created on 2018-09-11 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Ethically Conscious International Shares Index ETF seeks to track the return of the FTSE Developed ex Australia Choice Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax
π Performance (5Yr p.a)
13.74%
π Share price
$102.40 AUD
π GLOBAL
π€ TECHNOLOGY
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
Want more shares? Try these...